Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023

Upgrades

For Silvercorp Metals Inc SVM, Raymond James upgraded the previous rating of Market Perform to Outperform. Silvercorp Metals earned $0.04 in the second quarter, compared to $0.08 in the year-ago quarter. The current stock performance of Silvercorp Metals shows a 52-week-high of $4.20 and a 52-week-low of $1.99. Moreover, at the end of the last trading period, the closing price was at $3.31.

For LyondellBasell Industries NV LYB, Atlantic Equities upgraded the previous rating of Neutral to Overweight. For the third quarter, LyondellBasell Industries had an EPS of $1.96, compared to year-ago quarter EPS of $5.25. The stock has a 52-week-high of $117.22 and a 52-week-low of $71.46. At the end of the last trading period, LyondellBasell Industries closed at $94.46.

According to Goldman Sachs, the prior rating for Inter & Co Inc INTR was changed from Neutral to Buy. At the moment, the stock has a 52-week-high of $4.63 and a 52-week-low of $1.72. Inter & Co closed at $2.47 at the end of the last trading period.

According to William Blair, the prior rating for FibroGen Inc FGEN was changed from Market Perform to Outperform. FibroGen earned $0.98 in the third quarter, compared to $0.54 in the year-ago quarter. The stock has a 52-week-high of $22.63 and a 52-week-low of $7.81. At the end of the last trading period, FibroGen closed at $21.59.

See all analyst ratings upgrades.

Downgrades

For Sierra Bancorp BSRR, Hovde Group downgraded the previous rating of Outperform to Market Perform. In the fourth quarter, Sierra Bancorp showed an EPS of $0.47, compared to $0.63 from the year-ago quarter. At the moment, the stock has a 52-week-high of $27.24 and a 52-week-low of $19.62. Sierra Bancorp closed at $21.32 at the end of the last trading period.

For HomeStreet Inc HMST, Keefe, Bruyette & Woods downgraded the previous rating of Outperform to Market Perform. HomeStreet earned $0.45 in the fourth quarter, compared to $1.43 in the year-ago quarter. At the moment, the stock has a 52-week-high of $52.95 and a 52-week-low of $22.44. HomeStreet closed at $26.82 at the end of the last trading period.

For Q2 Holdings Inc QTWO, Baird downgraded the previous rating of Outperform to Neutral. In the third quarter, Q2 Holdings showed an EPS of $0.10, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $67.77 and a 52-week-low of $20.93. At the end of the last trading period, Q2 Holdings closed at $32.04.

For Bank of America Corp BAC, Atlantic Equities downgraded the previous rating of Overweight to Neutral. In the fourth quarter, Bank of America showed an EPS of $0.85, compared to $0.82 from the year-ago quarter. The current stock performance of Bank of America shows a 52-week-high of $50.11 and a 52-week-low of $29.31. Moreover, at the end of the last trading period, the closing price was at $35.30.

For Eastern Bankshares Inc EBC, JP Morgan downgraded the previous rating of Neutral to Underweight. For the fourth quarter, Eastern Bankshares had an EPS of $0.31, compared to year-ago quarter EPS of $0.26. The current stock performance of Eastern Bankshares shows a 52-week-high of $22.35 and a 52-week-low of $15.25. Moreover, at the end of the last trading period, the closing price was at $15.65.

For Invitae Corp NVTA, Goldman Sachs downgraded the previous rating of Neutral to Sell. NoneThe current stock performance of Invitae shows a 52-week-high of $12.04 and a 52-week-low of $1.67. Moreover, at the end of the last trading period, the closing price was at $2.48.

See all analyst ratings downgrades.

Initiations

Craig-Hallum initiated coverage on Xometry Inc XMTR with a Buy rating. The price target for Xometry is set to $48.00. For the third quarter, Xometry had an EPS of $0.11, compared to year-ago quarter EPS of $0.33. At the moment, the stock has a 52-week-high of $64.35 and a 52-week-low of $26.61. Xometry closed at $32.66 at the end of the last trading period.

For Cutera Inc CUTR, William Blair initiated coverage, by setting the current rating at Market Perform. NoneThe current stock performance of Cutera shows a 52-week-high of $74.38 and a 52-week-low of $26.52. Moreover, at the end of the last trading period, the closing price was at $33.79.

Wedbush initiated coverage on ARS Pharmaceuticals Inc SPRY with an Outperform rating. The price target for ARS Pharmaceuticals is set to $10.00. At the moment, the stock has a 52-week-high of $9.17 and a 52-week-low of $4.25. ARS Pharmaceuticals closed at $6.34 at the end of the last trading period.

Zacks Investment Research initiated coverage on Expion360 Inc XPON with a Buy rating. The price target for Expion360 is set to $4.25. In the third quarter, Expion360 showed an EPS of $0.19, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $11.29 and a 52-week-low of $0.90. Expion360 closed at $2.21 at the end of the last trading period.

Piper Sandler initiated coverage on Incyte Corp INCY with an Overweight rating. The price target for Incyte is set to $100.00. Incyte earned $0.60 in the third quarter, compared to $1.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $86.29 and a 52-week-low of $65.07. Incyte closed at $83.65 at the end of the last trading period.

With a Buy rating, EF Hutton initiated coverage on Onfolio Holdings Inc ONFO. The price target seems to have been set at $3.00 for Onfolio Holdings. In the third quarter, Onfolio Holdings showed an EPS of $0.31, compared to $0.30 from the year-ago quarter.

With a Buy rating, EF Hutton initiated coverage on Xencor Inc XNCR. The price target seems to have been set at $42.00 for Xencor. Xencor earned $0.55 in the third quarter, compared to $0.69 in the year-ago quarter. The stock has a 52-week-high of $35.92 and a 52-week-low of $19.36. At the end of the last trading period, Xencor closed at $31.70.

Stifel initiated coverage on Kura Oncology Inc KURA with a Buy rating. The price target for Kura Oncology is set to $25.00. For the third quarter, Kura Oncology had an EPS of $0.53, compared to year-ago quarter EPS of $0.50. At the moment, the stock has a 52-week-high of $19.93 and a 52-week-low of $10.41. Kura Oncology closed at $13.17 at the end of the last trading period.

Stifel initiated coverage on Syndax Pharmaceuticals Inc SNDX with a Buy rating. The price target for Syndax Pharmaceuticals is set to $37.00. In the third quarter, Syndax Pharmaceuticals showed an EPS of $0.58, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $28.90 and a 52-week-low of $13.27. Syndax Pharmaceuticals closed at $27.09 at the end of the last trading period.

See all analyst ratings initiations.